Ozempic Feet and Hands: Swelling, Heel Pain, Tingling and Numbness

“Ozempic feet” is not a diagnosis, and no trial has measured what a GLP‑1 does to the feet or hands. Three separate complaints travel under the name. Thinner, bonier-looking feet and a sore heel are a weight-loss question, and the studies of weight loss point toward less foot pain, not more. Swelling of the feet or ankles is not listed on any of the eight GLP‑1 labels we checked, so it needs another explanation. Tingling, burning or numbness is the one to take seriously: the labels list an altered-skin-sensation reaction, and case reports describe nerve injuries after fast weight loss, a fast drop in blood sugar, or weeks of vomiting.

Three questions under one phrase

Appearance and heel pain: the fat pad question

No published study has photographed or measured hands on a GLP‑1, and a PubMed search for one returns nothing relevant. The likely explanation is ordinary: these drugs cause large weight loss, and part of what is lost is the layer of fat under the skin everywhere, including the backs of the hands and the tops of the feet. Less padding makes veins, tendons and knuckles easier to see. That is inference from how weight loss works, not a finding from a study of the drugs. Some of the weight lost is lean tissue as well, which our page on hair loss and muscle loss on GLP-1s covers.

The popular explanation for sore heels is that the drug “melts” the cushioning fat beneath the heel and forefoot. Fat pad atrophy is a real condition. A 2025 review describes it as the loss of the cushioning fat beneath the foot, causing pain and a risk of skin breakdown, and surgeons treat it with fat grafting.^[15] But no study we could find has measured the plantar fat pad before and after weight loss of any kind, by surgery, diet or drug. In a 2025 ultrasound study of 35 young adults, body mass index was related to pad thickness at only one of the five points measured under the forefoot, and only moderately.^[14] On that evidence, the pad does not simply track body fat. Whether it thins on a GLP‑1 is unknown.

What has been measured points the other way. A systematic review found a strong link between a higher body mass index and chronic heel pain, though in 2011 there was little direct evidence that losing weight relieved it.^[9] Later studies filled some of that gap:

• Bariatric surgery, Australia. Twenty-nine people who had surgery were compared with 16 still on the waiting list. Six months later foot pain had fallen 35.7 points on a standard foot questionnaire. Foot posture did not change, and the drop in pressure under the foot did not explain the drop in pain.^[10] In the same group, higher fat mass at the start, not body mass index, predicted more pain later.^[11]
• Bariatric surgery, Cleveland Clinic. Of 163 people with plantar fasciitis who had surgery, 146 (90%) had it resolve, in a review of records rather than a trial.^[12]
• Semaglutide and heel pain, Shanghai. Among 2,902 adults with long-standing heel pain followed for at least two years, the 92 who took semaglutide for diabetes or weight had a larger improvement in pain, 14.9 points more on a foot-health questionnaire after adjustment. A further 30 patients given semaglutide all improved, but with no comparison group. The authors call for a randomized trial.^[13]

None of this proves a GLP‑1 helps a sore heel. It does mean that the claim that these drugs cause heel pain has no study behind it, and the weight-loss data lean toward relief. New heel or forefoot pain still deserves a look, because plantar fasciitis, stress fractures and nerve problems all start that way. A podiatrist can examine the pad directly, and cushioned shoes or insoles cost little to try. If you also have diabetes, foot checks matter for a separate reason, set out on our page on GLP-1s, foot ulcers and blood flow.

Swollen feet and ankles: not on the label

We searched the full current text of eight labels: Wegovy, Zepbound, Mounjaro, Ozempic, the Ozempic and Rybelsus tablets, Saxenda, Victoza and Trulicity. None lists peripheral edema, the medical term for fluid swelling of the legs and feet. Every mention of swelling is either a lump in the neck, in the thyroid-tumor warning, or swelling of the face, lips, tongue or throat, in the warning about serious allergic reactions.^[1][2] The Wegovy and Zepbound labels table every reaction seen in at least 2% of people and more often than on placebo, so leg swelling did not reach that bar in their weight-loss trials.^[1][2] The Ozempic and Mounjaro tables start at 5%, so their silence says a little less.^[3][4]

FDA’s adverse event database does hold reports. On October 17, 2026, reports naming semaglutide included 542 coded as peripheral swelling and 162 as peripheral edema, out of 73,001 semaglutide reports in all. For tirzepatide the figures were 381 and 107 out of 160,663.^[8] Anyone can file a report, the drug named may not be the cause, and the counts cannot be turned into a rate. They show that people notice swelling while on these drugs, which is expected for any common symptom in millions of users.

So swollen feet on a GLP‑1 usually have a cause that is not the GLP‑1. A family-medicine review sorts it this way:^[7]

• One leg, over hours to a few days: a deep vein clot, a skin infection, a burst cyst behind the knee, or a newly started calcium channel blocker such as amlodipine. A clot is the one not to wait on.
• Both legs, building slowly: most often weak leg veins, especially when swelling is worse at the end of the day. Sleep apnea can cause it too.
• Both legs with other symptoms: heart failure, kidney disease or liver disease. Breathlessness, waking at night short of breath, or rapid weight gain alongside swelling need prompt attention.
• Other medicines: the review’s list includes calcium channel blockers, anti-inflammatory painkillers such as ibuprofen, corticosteroids, and hormones including estrogen and testosterone.

One diabetes medicine belongs on that list. The label for pioglitazone (Actos) warns of dose-related edema and says drugs in its class can cause fluid retention that can bring on or worsen heart failure.^[6] People with type 2 diabetes sometimes take it alongside Ozempic or Mounjaro, and if the feet swell, it is the more likely suspect.

Tingling, burning and numbness: four different problems

This is where the hands-and-feet question gets medical. Numb or tingling feet on a GLP‑1 can come from at least four separate causes, and they are handled differently.

1. Dysesthesia, the reaction on the label

The labels do list one sensory reaction: dysesthesia, an unpleasant change in how the skin feels. Wegovy’s label groups burning, tingling, skin pain and over-sensitive skin under that heading.^[1] How often it happens depends heavily on the drug and the dose:

The Wegovy label says the reaction rose with the dose and with drug levels in the blood, and that it cleared faster when the dose was paused, lowered or stopped. Among people who had it on 7.2 mg, 18% had not recovered by the end of the trial.^[1] The Zepbound and Mounjaro labels use the single word dysesthesia.^[2][3] The longer list that includes hyperesthesia, meaning heightened sensitivity, appears only on Wegovy’s. Ozempic and the semaglutide tablets list it among reports received after approval.^[4][5] A French analysis of the World Health Organization’s reporting database found semaglutide and tirzepatide reported with heightened skin sensitivity more often than expected, and the pattern looked dose-related. That is a reporting signal, not a rate.^[24]

Dysesthesia is a skin-sensation reaction, not nerve damage, and it is the subject of our companion page on skin sensitivity, rash and itching on GLP-1s. The 7.2 mg figures are set out on what Wegovy 7.2 mg costs, and skin that hurts to the touch is also covered in joint pain, back pain and aches on GLP-1s.

2. A fast drop in blood sugar

People with diabetes whose blood sugar has been high for a long time can develop a painful neuropathy when it is brought down quickly. It is called treatment-induced neuropathy of diabetes. In a Boston clinic that assessed 954 people for diabetic neuropathy over five years, 104 (10.9%) met the definition: new nerve pain or nervous-system symptoms within eight weeks of an HbA1c drop of at least 2 points over three months. A drop of 2 to 3 points over three months carried about a 20% risk; a drop of more than 4 points carried a risk above 80%.^[16]

A 2026 review of 181 reported patients found burning pain in the feet was typical, most cases began four to eight weeks after treatment was stepped up, and most improved over months to a year, though some did not.^[17] The trigger is how fast blood sugar falls, not any one drug; insulin, tablets and diet changes have all been reported. A GLP‑1 can lower HbA1c by several points, and one published case on semaglutide included this diagnosis.^[22] The practical point is for people starting with a very high HbA1c: the pace of the drop is worth discussing with the prescriber.

3. Nerve pressure after fast weight loss

The fat around a nerve also protects it. When weight comes off quickly, a nerve that runs close to the skin can be pressed against bone. The best-known example is the peroneal nerve at the outside of the knee, and the result, called slimmer’s palsy, is foot drop: the front of the foot cannot be lifted, so it slaps or catches on stairs. Two case reports describe it on GLP‑1s:

• Two men on tirzepatide, who lost 50 pounds over five months and 30 pounds over three, developed foot drop within one to three days after habitual leg crossing. With no more leg crossing and physical therapy, it resolved over three to four months.^[19]
• Two people without diabetes developed sudden foot drop after losing 14% and 18% of body weight over three to six months on semaglutide and tirzepatide.^[20]

Hands can be affected by the same process higher up. One report describes a 60-year-old man who lost 60 pounds over six months on tirzepatide and developed shoulder-blade pain, tingling and arm weakness from the nerves at the base of the neck; it improved after the drug was stopped.^[21] Diabetes raises the risk of these pressure injuries at the wrist, the elbow and the knee.^[18] FDA’s database holds 19 reports of peroneal nerve palsy naming semaglutide and 45 naming tirzepatide, again reports and not proven cases.^[8] Nobody knows how often this happens. Avoiding long periods of leg crossing, kneeling or leaning on the elbows is sensible while weight is coming off fast.

4. Vitamin deficiency after weeks of vomiting

The rarest and most serious route runs through nutrition. A 65-year-old woman with diabetes lost 120 pounds over months on semaglutide with nausea and vomiting that would not settle. She developed severe numbness and weakness, and her thiamine, folate and vitamin B12 levels were low. Within five days of replacement she began to improve, with partial recovery.^[23] A 37-year-old woman on semaglutide developed numbness and weakness in both legs, then confusion, and was found to be thiamine-deficient.^[22] These are single cases. The lesson is that persistent vomiting with new numbness, weakness, confusion or blurred vision is an emergency, and thiamine is cheap to give.

And the neuropathy that was already there

Many people on Ozempic or Mounjaro have type 2 diabetes, and diabetic neuropathy is common in it: one in five people in tirzepatide’s heart-outcomes trial had it before they started.^[3] Numb feet noticed after starting a GLP‑1 may simply have been missed before. In US health records of 19,770 matched pairs with diabetic neuropathy, people starting a GLP‑1 had slightly fewer foot ulcers over a year than people starting a DPP-4 inhibitor (2.2% against 2.7%) but more Charcot foot, a collapse of the bones in a numb foot (0.3% against 0.2%). That is a records study and shows associations, not causes.^[25] Either way, a numb foot needs daily checks.

Cold hands and feet, and sweaty ones

No GLP‑1 label lists cold hands or feet, and none lists sweating as a side effect in its own right. Sweating appears in the Medication Guides as one sign of low blood sugar, alongside shakiness, a fast heartbeat and hunger, and the risk of low blood sugar is mainly with insulin or a sulfonylurea taken at the same time.^[2][4] Sudden sweaty, shaky, clammy hands are a reason to check blood sugar if you have diabetes.

Feeling cold all over after losing weight is a separate topic, covered in feeling cold and night sweats on GLP-1s. A foot that is cold on its own, especially with calf pain on walking, pale or bluish skin or slow-healing sores, raises a circulation question rather than a drug one, and in diabetes that is worth a prompt check.

When to see a clinician

• The same day: one swollen, painful leg; swelling of the face or throat; leg swelling with breathlessness; sudden foot drop or a weak hand; numbness or weakness with persistent vomiting, confusion or blurred vision.
• Within days: new swelling of both feet that does not go down overnight; burning or painful skin, especially after a dose increase; new numbness or tingling, particularly if your HbA1c has fallen fast.
• At the next visit: heel or forefoot pain that has lasted more than a few weeks, or feet that feel thin and bony when you walk. A podiatrist is the right person for the pad itself.
• With diabetes, always: any cut, blister or sore on a foot that has lost feeling.

Do not stop a GLP‑1 on your own for a mild symptom; for dysesthesia the label’s own data show that lowering or pausing the dose with a prescriber is what helps.^[1]